NEIL
JONES TO STEP DOWN AS |
BackMiami, FL, May 1,
2008 -- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced
that its Vice President of Marketing & Sales, W. Neil Jones, has
indicated that he plans to leave the company in order to pursue other
interests. Jones will remain with Noven for a transition period through
the end of May 2008. Noven is working with a national executive recruiting
firm to identify Jones’s successor.
"We thank Neil for
his many contributions to Noven, and wish him well in his future endeavors,"
said Jeffrey F. Eisenberg, Executive Vice President of Noven and President
of Novogyne Pharmaceuticals, Noven’s joint venture with Novartis
Pharmaceuticals Corporation. "During his 11-year tenure at Noven,
he helped establish a highly-effective and efficient marketing and
sales organization, with core competencies that are serving us well
as we build our specialty pharmaceutical business.” In connection
with his decision to leave the organization, Noven recognized Jones
with a career achievement award for his service.
"I am proud
to have played a role in building an outstanding marketing and sales
team," said Jones, “and I believe the team is well positioned
to continue to help Noven advance its growth strategy." About
Noven Noven Pharmaceuticals, Inc. is a specialty pharmaceutical company
engaged in the research, development, manufacture, marketing and sale
of prescription pharmaceutical products. Noven’s business and
operations are focused in three principal areas – transdermal
drug delivery, the Novogyne joint venture, and its Noven Therapeutics
specialty pharmaceutical unit.
About Noven
Noven Pharmaceuticals, Inc.
is a specialty pharmaceutical company engaged in the research, development,
manufacture, marketing and sale of prescription pharmaceutical products.
Noven’s business and operations are focused in three principal
areas – transdermal drug delivery, the Novogyne joint venture,
and its Noven Therapeutics specialty pharmaceutical unit.
Safe
Harbor Statement under the Private Litigation Reform Act of 1995
Except
for historical information contained herein, the matters discussed
in this press release contain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934 that involve substantial risks
and uncertainties. Statements that are not historical facts, including
statements that are preceded by, followed by, or that include, the
words “believes,” “anticipates,” “plans,” “expects” or
similar expressions and statements are forward-looking statements.
Noven’s estimated or anticipated future results, product performance
or other non-historical facts are forward-looking and reflect Noven’s
current perspective on existing trends and information. Actual results,
performance or achievements could differ materially from those contemplated,
expressed or implied by the forward-looking statements contained herein.
These forward-looking statements are based largely on the current expectations
of Noven and are subject to a number of risks and uncertainties that
are subject to change based on factors that are, in many instances,
beyond Noven's control.
These forward-looking statements include the
risk that, for any number of reasons, Noven may not achieve its longer-term
growth objectives and other goals. For additional information regarding
these and other risks associated with Noven’s business, readers
should refer to Noven’s Annual Report on Form 10-K as well as
other reports filed from time to time with the Securities and Exchange
Commission. Unless required by law, Noven undertakes no obligation
to publicly update or revise any forward-looking statements, whether
as a result of new information, future events, or otherwise.
Contact:
|
Copyright © 2008 Noven Pharmaceuticals, Inc. All rights reserved.